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Abstract
Background: Sciatica is a severe, disabling condition that lacks high quality evidence for effective treatment
strategies. This a priori statistical analysis plan describes the methodology of analysis for the PRECISE study.
Methods/design: PRECISE is a prospectively registered, double blind, randomised placebo controlled trial of
pregabalin compared to placebo, in addition to usual care in patients with sciatica. The aim of this study is to
determine the efficacy and cost-effectiveness of pregabalin in reducing leg pain intensity (primary outcome).
Secondary outcomes include disability (key secondary), back pain intensity, quality of life, participants’ perceived global
effect, work absenteeism and health utilisation. Information about medication usage and tolerability are also collected.
Outcomes are collected over one year (weeks 2, 4, 8, 12, 26 and 52). Double data entry will be conducted for primary
and key secondary outcomes. Other outcomes will be checked using a risk-based approach. Analyses will be consistent
with the intention-to-treat principle. Statistical tests will be two-tailed with a p value <0.05 considered significant.
Group allocation will remain masked until analyses and interpretation are finalised. Repeated-measure linear mixed
models will assess the effect of treatment (pregabalin versus placebo) on primary and secondary outcomes at all time
points. Fixed effects will include group allocation, visit as a categorical variable and the interaction between group and
visit. Covariates will include baseline leg pain and symptom duration, with an interaction term between baseline leg
pain and visit. Pairwise differences between groups will be tested at weeks 8 and 52. The number of serious adverse
events and adverse events will be reported, and the proportion of patients per group who have at least one event will
be compared using Fisher’s exact test. An economic evaluation will be conducted if there is a treatment effect on the
primary outcome at week 8. A subgroup analysis will assess whether presenting features of neuropathic pain at
baseline modify the treatment effect of leg pain at week 8.
Discussion: This statistical analysis plan provides detailed methodology for the analysis of the PRECISE study, which
aims to deliver much needed evidence about effective and affordable management of sciatica.
Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN12613000530729. Registered 13
May 2013)
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Update
Sciatica is a severe, disabling condition characterised by
radiating leg pain, with or without low back pain. There
is limited high quality evidence for effective, conservative
treatment strategies for patients with sciatica [1]. Prega-
balin is a neuropathic pain medicine that may reduce leg
pain in these patients; however, its use in this population
is not informed by high quality direct evidence.
PRECISE is a randomised placebo-controlled trial
evaluating the efficacy of pregabalin, in patients with sci-
atica, in addition to usual care [2]. Participant recruit-
ment commenced in September 2013 and completed in
March 2015. Data collection will be completed in April
2016. This statistical analysis plan details the planned
analyses for the PRECISE study to facilitate transparency
of data analysis. The statistical analysis plan was ap-
proved and signed by study investigators on 28
November 2015. Statistical analysis will be performed
following data integrity checks and locking (estimated
April 2016).
Study overview
Trial design
PRECISE is a double-blind, randomised placebo-
controlled trial of pregabalin compared to placebo, in
addition to usual care, investigating the efficacy and
cost-effectiveness of pregabalin in patients with sciatica.
The study received ethics approval from the University
of Sydney Human Research Ethics Committee (protocol
number 15333), was prospectively registered at the
Australian and New Zealand Clinical Trials Registry
(ACTRN12613000530729) and the study protocol has
been published [2].
Study population
Two hundred and nine eligible consenting participants
who were seeking care for their back-related leg pain
(sciatica) were recruited from primary care (n = 45 sites)
or outpatient specialist clinics (n = 2 sites). Eligible par-
ticipants were adults with radiating leg pain below the
knee, of at least one week but no longer than one year
in duration, which caused at least moderate pain or
interference with work or daily activities in the last week.
Participants had to have signs or symptoms of nerve
root or spinal nerve involvement, as demonstrated by ei-
ther myotomal weakness, dermatomal deficits, dimin-
ished reflexes or leg pain radiating in a dermatomal
distribution, and had to have sufficient understanding of
the English language or assistance with interpretation to
allow completion of the study treatment and assess-
ments. Participants were excluded if they had any known
or suspected serious spinal pathology; were scheduled
for spinal surgery or interventional procedures for sciat-
ica during the 8-week treatment period; were pregnant,
breastfeeding or planning conception during the inter-
vention period; had taken pregabalin or gabapentin for
this current episode of sciatica; were taking an anticon-
vulsant medication, a neuropathic pain medication, a tri-
cyclic antidepressant or a sedative and unable to cease
the medication; were suffering from severe depression or
suicidal thoughts (score of ≥20 on the Patient Health
Questionnaire (PHQ-9) or a score of 2 or 3 on question
9); or had a contraindication(s) to pregabalin.
Intervention
All participants received advice (reassurance, advice
to stay active and avoid prolonged bed rest) and a
study medication pack containing either pregabalin or
placebo. Participants commenced by taking one
75 mg capsule, twice daily. Follow-up consultations
(once a week for up to 8 weeks) with a study doctor
monitored individual progress, tolerability and adverse
events to titrate the dosage to the participant’s opti-
mal dose, up to a maximum 600 mg per day. ‘Ad-
equate improvement’ was defined as a pain rating of
0 or 1 out of 10, for leg pain, for a minimum of
72 hours, with no or tolerable side effects. If adequate
improvement was achieved before the maximum
8 week regimen was completed, early titration down
to cessation was possible. In addition, usual care
could be provided by the study doctor to all partici-
pants during the study and could include a referral
for physical or manual therapy and/or prescription of
analgesic medication. It was recommended that the
study doctors follow the World Health Organisation
(WHO) pain ladder [3] for analgesic medication pre-
scription, and refrain from prescribing additional
medicines for neuropathic pain (for example, antide-
pressants, selective serotonin and noradrenaline
reuptake inhibitors, gabapentin and other anticonvul-
sant medications) or scheduling interventional proce-
dures. The maximum treatment period was 8 weeks.
Randomisation and allocation
Study medicines were packaged and labelled accord-
ing to a pre-generated random number sequence;
each sealed box had a unique participant number. Al-
location to either group (pregabalin or placebo) was
at a 1:1 ratio. All study medicines were identical in
appearance. The study doctor provided a pre-
packaged study medication pack to each eligible par-
ticipant. All study personnel, study clinicians and par-
ticipants were blind to the group allocation. A
participant was considered randomised into the study
once informed consent and baseline data were ob-
tained and the participant was instructed to break the
seal on the study medicine.
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Outcome variables
Outcomes were collected at baseline and at weeks 2, 4,
8, 12, 26 and 52 (unless otherwise stated). Data were col-
lected either by telephone, where a research assistant
first entered the data on paper (source data) and then
transcribed the data into the study electronic database,
or by participants completing the study questionnaires
online, with the data directly entered into the secure
electronic database. Manual data checking procedures
ensured correctness of data transfer of source data.
The primary outcome was leg pain intensity, measured
by a Numeric Pain Rating Scale (NPRS). The NPRS asks
participants to rate their leg pain on a scale of 10, with 0
being ’no leg pain’ and 10 being the ’worst pain imagin-
able’, as an average over the last 24 hours [4]. The pri-
mary time point was week 8.
Secondary outcomes were:
 Disability, measured using the Roland-Morris Dis-
ability Questionnaire for Sciatica [5]. It was the key
secondary outcome.
 Back pain intensity, measured using the NPRS [4].
 Quality of life, measured using the Short Form
Health Survey 12, version 2 (SF-12v2) questionnaire
[6].
 Global Perceived Effect asks the participant to
compare their leg pain to that experienced when
commencing the trial and was measured on a Likert
scale, from −5 vastly worse, to 0 unchanged, to +5
completely recovered [7].
 Work absenteeism, self-reported number of hours
missed from paid employment due to leg pain
(collected by self-report at weeks 4, 12, 26 and 52).
Use of health services such as physiotherapy and use
of medication for leg pain (other than the study
medicine) (collected by self-report at weeks 4, 12, 26
and 52).
Additional data collected:
 Physical examination findings and level of nerve root
involvement: at screening, the study doctor was
asked to assess lower limb sensory, motor and reflex
functions and provide their diagnosis on the level of
the nerve root involved.
 Participant details: age, gender, self-reported height
and weight.
 Socio-demographic details: health insurance status,
employment status and household income.
 Episode details: leg pain duration, compensation
status and medicine(s) use for leg pain one week
preceding enrollment.
 Presence of neuropathic pain: evaluated at baseline
using the painDETECT questionnaire [8].
 Details of serious adverse events and adverse events
were collected, as well as confirmed pregnancy for
both female and male (that is, partner pregnancy)
participants up to week 12. Serious adverse events
were defined as an event that was life threatening,
resulted in death, hospitalisation, or significant
disability. Adverse events were defined as any
untoward medical occurrence as reported by the
participant that may or may not be related to the
study treatment.
 Study medication: study doctors were asked to
record the prescribed study medication dosage for
each participant weekly until medication cessation.
Participants were asked to complete a diary,
recording the daily consumption of study
medication until cessation and to return any unused
medicines at the end of week 8. All returned
medicines were counted and documented before
secure destruction.
 Treatment satisfaction: participants were asked to
rate, on a 5-point scale (extremely dissatisfied,
dissatisfied, neutral, satisfied or extremely satisfied)
how satisfied they were overall with the study
treatment at week 8.
 Participant blinding to treatment: participants were
asked to guess to which study treatment they were
randomised (pregabalin, placebo or don’t know) at
week 8.
Power and sample size
A required sample size of 204 participants (102 per
group) was calculated with 90 % power to detect a dif-
ference of 1.5 units of leg pain out of the 10-unit NPRS
at week 8. This assumed a standard deviation of 2.5 [9]
and a two-tailed alpha of 0.05, and allowed for 10 % of
dropouts and 20 % non-compliance. The between-group
difference of 1.5 units out of 10 in leg pain was based on
previous trials of pregabalin for neuropathic pain condi-
tions [10]. The sample size also had 90 % power to de-
tect a difference between groups of 3 on the 23-point
Roland-Morris Disability Questionnaire for Sciatica, the
key secondary outcome, at week 8. This was based on
the between-group difference of 3 and standard devi-
ation of 4 from one of our previous sciatica trials [9],
and the same assumptions taken for the primary out-
come calculation.
Statistical analysis
Analysis principles
Two analysts, blind to group allocation, will conduct in-
dependent analyses of the primary and key secondary
outcomes. Results will be compared and discrepancies
resolved. Other analyses will be conducted by one ana-
lyst with the codes reviewed by a senior statistician. A
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dummy dataset will be used to confirm statistical proce-
dures, with discrepancies resolved before unblinding.
Analyses will be consistent with the intention-to-treat
principle. Participants will be analysed according to
group allocation, estimating the mean difference at week
8 between pregabalin and placebo treatment groups
regardless of the treatments received after randomisa-
tion. All statistical tests will be two-tailed and a p value
of <0.05 considered significant. Continuous variables will
be summarised using standard measures of central ten-
dency and dispersion, either as mean and standard error,
or median and interquartile range. Dichotomous or cat-
egorical variables will be summarised by frequencies or
denominators and percentages. Percentages will be cal-
culated using the number of participants for whom data
is available as the denominator. Analyses will be con-
ducted using SAS software version 9.3 or above (SAS In-
stitute Inc. 2012). No interim analysis will be conducted
or has been planned, as pregabalin is used under its ap-
proved label use.
Data integrity
Integrity of trial data is monitored regularly by scrutinis-
ing data files for omissions and errors. Double data entry
will be conducted for the primary (leg pain intensity)
and key secondary (disability) outcomes. Other out-
comes (that is, secondary outcomes excluding the key
secondary) will be checked using a risk-based approach.
This approach will be used for data collected by
telephone, in which a random 10 % sample of partici-
pants’ paper files (source data) will be cross-checked
against the electronic database. If the rate of error is
greater than 10 %, another 10 % sample is drawn and
checked. The acceptable error rate for this new sample
is then 9 %. If the error rate is again higher than the ac-
ceptable rate (9 %), then another 10 % sample is drawn
for checking and the next acceptable error rate is re-
duced by another 1 %. This process continues until the
observed error rate is below the acceptable threshold.
All inconsistencies will be investigated and rectified. For
participants who directly completed their question-
naire(s) online, no cross-checking is required. Range
checks will be performed on all variables.
Blinding
All researchers involved in the preparation of the ana-
lysis plan had no access to trial data broken down by
treatment allocation. Once data quality checks are
satisfactory and the database is locked, we will under-
take a blind review to quantify missing data of the
Assessed for eligibility (n= XX)
Excluded (n= XX)
• Not meeting inclusion criteria (n= XX)
• Declined to participate (n= XX)
• Other reasons (n= XX)
Analysed (n= XX)
• Excluded from analysis (reasons) (n= XX)
Lost to follow-up (reasons) (n= XX)
Discontinued intervention
• side effects (n= XX)
• other reasons (n= XX)
Allocated to pregabalin group (n= XX)
•Received allocated intervention (n= XX)
•Did not receive allocated intervention
(reasons) (n= XX)
Lost to follow-up (reasons) (n= XX)
Discontinued intervention
• side effects (n= XX)
• other reasons (n= XX)
Allocated to placebo group (n= XX)
•Received allocated intervention (n= XX)
•Did not receive allocated intervention
(reasons) (n= XX)
Analysed (n= XX)
• Excluded from analysis (reasons) (n= XX)
Allocation
Analysis
Follow-Up
Randomised (n= XX)
Enrollment
Fig. 1 Flow of study participants (CONSORT) flow diagram
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Table 1 Participant baseline characteristics
Pregabalin (n = xxx) Placebo (n = xxx)
Participant characteristics
Female n/N (%) n/N (%)
Age (years) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
BMI (kg/m2) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Currently employed n/N (%) n/N (%)
Compensable leg pain n/N (%) n/N (%)
Household income/week (year) (AUD)
No income n/N (%) n/N (%)
$1–$649 ($1–$33,799) n/N (%) n/N (%)
$650–$1699 ($33,800–$88,399) n/N (%) n/N (%)
$1700–$3999 ($88,400–$207,999) n/N (%) n/N (%)
$4000 or more ($208,000 or more) n/N (%) n/N (%)
Chose not to answer n/N (%) n/N (%)
Medicine use in the last weeka
Simple analgesics n/N (%) n/N (%)
NSAIDs n/N (%) n/N (%)
Strong opioid analgesics n/N (%) n/N (%)
Combination opioid analgesics n/N (%) n/N (%)
Other n/N (%) n/N (%)
Occupation
Manager n/N (%) n/N (%)
Technician and Trade Worker n/N (%) n/N (%)
Clerical and Administrative Worker n/N (%) n/N (%)
Machinery Operator and Driver n/N (%) n/N (%)
Professional n/N (%) n/N (%)
Community and Personal Service Worker n/N (%) n/N (%)
Sales Worker n/N (%) n/N (%)
Labourer n/N (%) n/N (%)
Health insurance
None n/N (%) n/N (%)
Private hospital only n/N (%) n/N (%)
Private ancillary (extras) only n/N (%) n/N (%)
Private hospital and ancillary (extras) n/N (%) n/N (%)
DVA n/N (%) n/N (%)
Chose not to answer n/N (%) n/N (%)
Episode characteristics
Physical examination
Dermatomal pain n/N (%) n/N (%)
Neurological deficit n/N (%) n/N (%)
Sensory deficit n/N (%) n/N (%)
Motor deficit n/N (%) n/N (%)
Clinician diagnosis
Spinal level affected -L3 n/N (%) n/N (%)
Spinal level affected -L4 n/N (%) n/N (%)
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entire dataset (that is, not separated by group) and
allow for any final amendments to the statistical ana-
lysis plan. During analysis and interpretation, group
allocation will be masked using dummy group names
(for example, group A, group B). The true group allo-
cation will be unmasked only after the final statistical
report has been completed and interpretation agreed
upon.
Methods for handling missing data
In case more than 10 % of the primary outcome data
(leg pain intensity) at week 8 is missing, multiple impu-
tations will be used to conduct sensitivity analyses for
the longitudinal linear mixed model of the primary out-
come. Ten imputations using chained equations will be
used to replace missing leg pain data across all visits. In
addition to the outcome itself, the imputation model will
include a range of prognostic baseline variables. The
need to impute as well as the list of prognostic variables
for the multiple imputations will be confirmed at the
time of the blind review.
Trial profile
The flow of participants through the study will be re-
ported and will comply with the Consolidated Standards
of Reporting Trials (CONSORT) (Fig. 1).
Evaluation of demographics and baseline characteristics
Descriptive statistics of the baseline characteristics
will be presented by treatment group (Table 1) and
will include participant and episode characteristics.
Primary analyses
Repeated-measure linear mixed models will be used
to assess the effect of treatment (pregabalin versus
placebo) on leg pain intensity at all time points
(weeks 2, 4, 8, 12, 26 and 52). Fixed effects will in-
clude group allocation, visit as a categorical variable
and the interaction between group and visit. In
addition, baseline leg pain (NPRS score) and symptom
duration (days of symptom duration at baseline) will
be included as covariates (Table 2) with an interaction
term between baseline leg pain and visit. For every
time point, we will calculate the adjusted mean leg
pain score (NPRS score) per group as well as corre-
sponding 95 % confidence intervals. We will formally
test adjusted mean differences between groups at the
week 8 and week 52 time points (Table 2) with week
8 as the primary comparison. We will consider an ef-
fect size to be clinically significant if there is a
between-group difference of 1.5 units of leg pain out
of 10 units on the NPRS. Within patient correlations
will be modelled using a repeated effect and a com-
pound symmetry covariance structure. As sensitivity
analyses, the model will also be run using a heteroge-
neous compound symmetry structure and a spatial
power structure.
Secondary analyses
Secondary outcomes, with the exception of work absen-
teeism, health service utilisation and medicine use, will
be analysed using the same method as the primary ana-
lysis (longitudinal linear models) to evaluate the effect of
Table 1 Participant baseline characteristics (Continued)
Spinal level affected -L5 n/N (%) n/N (%)
Spinal level affected -S1 n/N (%) n/N (%)
Spinal level affected -S2 n/N (%) n/N (%)
Multiple spinal levels affected n/N (%) n/N (%)
Not reported n/N (%) n/N (%)
Leg pain duration (days) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Leg pain intensity (NPRS) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Back pain intensity (NPRS) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Disability (Roland Disability Questionnaire Sciatica) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Quality of life-physical score (SF-12v2) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Quality of life-mental score (SF-12v2) xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Global Perceived Effect scale xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
painDETECT score
score≤ 12 (neuropathic component unlikely) n/N (%) n/N (%)
score 13–18 (unclear if neuropathic pain present) n/N (%) n/N (%)
score≥ 19 (neuropathic component likely) n/N (%) n/N (%)
Abbreviations: DVA Department of Veterans’ Affair, NPRS Numeric Pain Rating Scale, SF-12v2 Short Form Health Survey 12, version 2
aExamples of medicines include simple analgesics such as paracetamol, NSAIDs such as ibuprofen, strong opioid analgesic such as oxycodone and combination
opioid analgesics such as paracetamol/codeine preparations
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Table 2 Results of longitudinal linear mixed model and Fisher exact test for primary and secondary outcomes (in mean and SE for
continuous data, number and percentage for count data)
Adjusted mean (SE)
Pregabalin (n = xxx) Placebo (n = xxx) Mean difference (95 % CI) {p value}
Leg pain intensity (NPRS)
Week 2 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 4 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 8 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Week 12 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 26 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 52 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Disability (RDQS)
Week 2 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 4 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 8 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Week 12 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 26 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 52 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Back pain intensity (NPRS)
Week 2 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 4 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 8 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Week 12 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 26 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 52 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Global Perceived Effect
Week 2 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 4 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 8 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Week 12 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 26 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 52 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Quality of life - physical score (SF12-v2)
Week 2 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 4 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 8 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Week 12 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 26 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 52 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Quality of life - mental score (SF12-v2)
Week 2 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 4 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 8 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
Week 12 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 26 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n
Week 52 xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x), n xx.x (xx.x to xx.x) {p value}
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the intervention over one year (Table 2). We will test
pairwise differences between groups for secondary out-
comes at the week 8 and week 52 time points (Table 2).
We will consider an effect size to be clinically significant
if there is a between-group difference of 1.5 units out of
10 units on the NPRS for back pain [10], and 3 points
on the 23-point scale Roland-Morris Disability Ques-
tionnaire for Sciatica for disability [9]. Work absenteeism
and health services utilisation will be calculated as the
cumulative number between baseline and week 52, ana-
lysed using analysis of covariance (ANCOVA), adjusted
for symptom duration. Use of medicine(s) (that is, co-
intervention) will be calculated as the percentage of par-
ticipants reporting to be taking at least one medicine
(other than the study medicine) for their leg pain and
differences compared between groups using the Fisher
exact test.
Evaluation of serious adverse events and adverse events
All participants reporting serious adverse events were
systematically investigated at the time of being reported
for potential association with the study treatment. Ser-
ious adverse events and adverse events will be coded
into categories according to the World Health Organisa-
tion’s International Classification of Diseases (ICD-10)
using three-digit codes [11]. For each category, we will
report the number of events and compare the propor-
tion of patients with at least one event between groups
using Fisher’s exact test (Table 3).
Evaluation of adherence to the study treatment
Adherence to the study treatment will be defined as hav-
ing consumed ≥80 % of the study medicine (measured
by self-report in the medication diary) against the study
doctor’s prescription [12]. This will be supported by the
participant’s returned medication count (Table 4).
Evaluation of participant blinding and satisfaction to
treatment
The number of participants reporting to which group
they thought they were allocated and the number of par-
ticipants reporting their level of satisfaction with the
study treatment will be reported per group (Table 4).
Economic evaluation
Economic evaluation will be conducted if there is a
treatment effect on the primary outcome at week 8. It
would entail a cost-utility analysis in which the interven-
tion will be assessed in terms of its incremental cost per
quality-adjusted life year (QALY). As we do not expect
any effect on survival, our QALY estimates will be based
exclusively on health state utilities. These will be ob-
tained from measures derived from the SF-12 and trans-
formed into health state utilities via the SF-6D algorithm
[13]. For each participant, these utilities will be averaged
out between observations over the entire duration of
follow-up of one year. The primary analysis will be con-
ducted from the perspective of the health sector. Health-
care services and medicines will be valued using
Table 2 Results of longitudinal linear mixed model and Fisher exact test for primary and secondary outcomes (in mean and SE for
continuous data, number and percentage for count data) (Continued)
Work absenteeism
Hours absent from work xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x) {p value}
Use of other treatments
Participants using other medicines {Fisher test} n/N (%) n/N (%) xx.x (xx.x to xx.x) {p value}
Participants using health services n/N (%) n/N (%) xx.x (xx.x to xx.x) {p value}
Abbreviations: SE standard error, NPRS Numeric Pain Rating Scale, RDQS Roland-Morris Disability Questionnaire Sciatica
Model terms include visit (categorical), treatment by visit interaction, baseline leg pain, baseline symptom duration and baseline leg pain by visit interaction
Table 3 Serious adverse events and adverse events reported. Events grouped using International Classification of Diseases (ICD10)
categories
Pregabalin (n = xxx) Placebo (n = xxx) {p value}
Serious adverse events
Total {Fisher test} nevt npat (%) nevt npat (%) {p value}
Adverse events
Total {Fisher test} nevt npat (%) nevt npat (%) {p value}
Adverse event A nevt npat (%) nevt npat (%)
Adverse event B nevt npat (%) nevt npat (%)
And so on nevt npat (%) nevt npat (%)
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published sources where possible. An additional analysis
will entail a societal perspective, including costs associ-
ated work absenteeism because of sciatica. Costs of ab-
senteeism from paid employment will be estimated by
the number of days absent from work multiplied by the
average wage rate. The incremental cost per QALY will
be estimated as the ratio of the difference in average cost
and QALYs between intervention arms. If required, a
sensitivity analysis will test uncertainty in key parameters
such as the selection of cost weights and statistical vari-
ation in quality of life scores.
Subgroup analyses
A planned subgroup analysis [2] will be conducted on the
primary outcome assessing neuropathic pain features of
participants at baseline to determine role of neuropathic
pain as a modifier of treatment effects at week 8. This will
be conducted using linear mixed models with the addition
of neuropathic pain and its interaction with the allocation
group. We will use the recommended cut-off values of the
painDETECT questionnaire [8] to categorise the presence
of neuropathic pain: a score ≥19 represents that a neuro-
pathic component is likely (>90 %); a score ≤12 represents
that neuropathic pain is unlikely (<15 %); a score between
13–18 indicates that it is unclear if neuropathic pain is
present.
Conclusion
The PRECISE study aims to provide much needed evi-
dence about effective and affordable management of the
debilitating symptoms of sciatica. This statistical analysis
plan details the study’s planned analyses, to aid transpar-
ency of results, and may assist the design of studies in
the future.
Trial status
Participant recruitment was completed in late March
2015 and follow-up outcomes will be collected by early
April 2016.
Abbreviations
ANCOVA: analysis of covariance; CI: confidence interval;
CONSORT: Consolidated Standards of Reporting Trials; NPRS: Numeric Pain
Rating Scale; PHQ-9: Patient Health Questionnaire; QALY: quality-adjusted life
year; SE: standard error; SF-12v2: Short Form Health Survey 12, version 2.
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The study medications were provided by in-kind support from Pfizer
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Table 4 Result of process variables (in mean and SE for continuous data, number and percentage for count data)
Pregabalin (n = xxx) Placebo (n = xxx)
Self-reported daily dose (mg/day)
Week 1 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 2 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 3 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 4 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 5 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 6 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 7 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Week 8 xxx.x (xxx.x to xxx.x), n xxx.x (xxx.x to xxx.x), n
Participants returning study medicines n/N (%) n/N (%)
Participants consuming ≥80 % prescribed dose
Medication diary n/N (%) n/N (%)
Returned medicine count n/N (%) n/N (%)
Assessment of participant blinding
Pregabalin n/N (%) n/N (%)
Placebo n/N (%) n/N (%)
Don’t know n/N (%) n/N (%)
Treatment satisfaction
Very dissatisfied n/N (%) n/N (%)
Dissatisfied n/N (%) n/N (%)
Neutral n/N (%) n/N (%)
Satisfied n/N (%) n/N (%)
Very satisfied n/N (%) n/N (%)
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